IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
0.760
-0.060 (-7.35%)
Nov 7, 2024, 3:32 PM EST - Market open
IceCure Medical Employees
As of December 31, 2023, IceCure Medical had 77 total employees, including 71 full-time and 6 part-time employees. The number of employees increased by 5 or 6.94% compared to the previous year.
Employees
77
Change (1Y)
5
Growth (1Y)
6.94%
Revenue / Employee
$43,325
Profits / Employee
-$177,727
Market Cap
37.62M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 77 | 5 | 6.94% |
| Dec 31, 2022 | 72 | 8 | 12.50% |
| Dec 31, 2021 | 64 | 17 | 36.17% |
| Dec 31, 2020 | 47 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| NeueHealth | 1,252 |
| LakeShore Biopharma | 758 |
| Apyx Medical | 252 |
| Achilles Therapeutics | 215 |
| Exagen | 179 |
| ProPhase Labs | 113 |
| CollPlant Biotechnologies | 75 |
| DURECT | 58 |
ICCM News
- 9 days ago - Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders - PRNewsWire
- 17 days ago - IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System - PRNewsWire
- 4 weeks ago - IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference - PRNewsWire
- 6 weeks ago - IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate - PRNewsWire
- 7 weeks ago - Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues - PRNewsWire
- 2 months ago - IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024 - PRNewsWire
- 2 months ago - IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences - PRNewsWire
- 2 months ago - USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies - PRNewsWire